10 July 2026
Helios Underwriting plc
('Helios' or 'the Company')
Issue of Equity
Further to the announcement made on 3 July 2026, the Company confirms that, pursuant to the scrip dividend alternative offered in lieu of cash for the final dividend for the year ended 31 December 2025, it has issued 823,838 new ordinary shares of 10p each ("Ordinary Shares") in satisfaction of elections received.
Application has been made to the London Stock Exchange for the new Ordinary Shares, which rank pari passu with the Company's existing issued Ordinary Shares, to be admitted to trading on AIM ('Admission'). Dealings are expected to commence at 8.00 a.m. on 10 July 2026. Following Admission pursuant to the scrip dividend elections received, the Company's issued share capital will consist of 76,040,011 Ordinary Shares. The Company holds 5,937,714 Ordinary Shares in Treasury. The total number of voting rights in the Company is therefore 70,102,297 Ordinary Shares.
For further information, please contact:
Helios Underwriting plc
Louis Tucker - Chief Executive Officer +44 (0)20 3965 6441
Adhiraj Maitra - Director of Finance and Operations +44 (0)20 3743 2114
Peel Hunt (Nomad, Broker and Financial Adviser)
Dan Webster / Andrew Buchanan / Martin Frowde +44 (0)20 7418 8900
Singer Capital Markets (Joint Broker)
Charles Leigh-Pemberton / Russell Cook / James Todd +44 (0)20 7496 3000
FTI Consulting
Ed Berry +44 (0)7703 330 199
Christian Harte +44 (0)7974 288 763
About Helios
Helios provides a limited liability direct investment into the Lloyd's insurance market and is quoted on the London Stock Exchange's AIM market (ticker: HUW). Helios trades within the Lloyd's insurance market. The portfolio provides a broad spread of business primarily participating in the US and other international wholesale and reinsurance markets. For further information please visit www.huwplc.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END IOEFIFFEDAIILIR